These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37778952)
1. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952 [TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. Yang JC; Han B; De La Mora Jiménez E; Lee JS; Koralewski P; Karadurmus N; Sugawara S; Livi L; Basappa NS; Quantin X; Dudnik J; Ortiz DM; Mekhail T; Okpara CE; Dutcus C; Zimmer Z; Samkari A; Bhagwati N; Csőszi T J Thorac Oncol; 2024 Jun; 19(6):941-953. PubMed ID: 38159809 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A; Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178 [TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS; Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993 [TBL] [Abstract][Full Text] [Related]
5. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK; N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. Necchi A; Van der Heijden MS; Trukhin D; Peer A; Gurney H; Alekseev BY; Parnis FX; Leibowitz R; De Santis M; Grivas P; Clark J; Munteanu M; Kataria R; Jia C; Balar AV; de Wit R BMC Cancer; 2024 Jul; 23(Suppl 1):1252. PubMed ID: 39054491 [TBL] [Abstract][Full Text] [Related]
7. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK; J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898 [No Abstract] [Full Text] [Related]
8. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Kawazoe A; Xu RH; García-Alfonso P; Passhak M; Teng HW; Shergill A; Gumus M; Qvortrup C; Stintzing S; Towns K; Kim TW; Shiu KK; Cundom J; Ananda S; Lebedinets A; Fu R; Jain R; Adelberg D; Heinemann V; Yoshino T; Elez E; J Clin Oncol; 2024 Aug; 42(24):2918-2927. PubMed ID: 38833658 [TBL] [Abstract][Full Text] [Related]
9. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658 [TBL] [Abstract][Full Text] [Related]
10. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. Cicin I; Plimack ER; Gurney H; Leibowitz R; Alekseev BY; Parnis FX; Peer A; Necchi A; Bellmunt J; Nishiyama H; Clark J; Munteanu M; Kataria R; Jia C; Powles T; Sternberg CN BMC Cancer; 2024 Jul; 23(Suppl 1):1256. PubMed ID: 39054485 [TBL] [Abstract][Full Text] [Related]
11. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725 [TBL] [Abstract][Full Text] [Related]
13. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418 [TBL] [Abstract][Full Text] [Related]
14. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363 [TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731 [TBL] [Abstract][Full Text] [Related]
16. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T; Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371 [TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453 [TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]